FDA approves Akeega for BRCA-positive metastatic prostate cancer

by

The U.S. Food & Drug Administration has approved Akeega (niraparib and abiraterone acetate) for the treatment of BRCA-positive metastatic castration-resistant prostate cancer.

Leave A Comment

Your email address will not be published. Required fields are marked *